ATE429216T1 - Alpha 2b oder 2b/2c adrenozeptor-agonisten zur behandlung von morbus alzheimer und morbus parkinson - Google Patents
Alpha 2b oder 2b/2c adrenozeptor-agonisten zur behandlung von morbus alzheimer und morbus parkinsonInfo
- Publication number
- ATE429216T1 ATE429216T1 AT03774642T AT03774642T ATE429216T1 AT E429216 T1 ATE429216 T1 AT E429216T1 AT 03774642 T AT03774642 T AT 03774642T AT 03774642 T AT03774642 T AT 03774642T AT E429216 T1 ATE429216 T1 AT E429216T1
- Authority
- AT
- Austria
- Prior art keywords
- disease
- alpha
- parkinson
- alzheimer
- treatment
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- 108060003345 Adrenergic Receptor Proteins 0.000 title 1
- 102000017910 Adrenergic receptor Human genes 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 230000000979 retarding effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41704902P | 2002-10-08 | 2002-10-08 | |
| PCT/US2003/031809 WO2004032913A1 (en) | 2002-10-08 | 2003-10-07 | Alpha 2b 0r 2b/2c adrenoceptor agonists for the treatment of neurodegeneration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE429216T1 true ATE429216T1 (de) | 2009-05-15 |
Family
ID=32093954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03774642T ATE429216T1 (de) | 2002-10-08 | 2003-10-07 | Alpha 2b oder 2b/2c adrenozeptor-agonisten zur behandlung von morbus alzheimer und morbus parkinson |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20040138312A1 (de) |
| EP (1) | EP1549305B1 (de) |
| JP (2) | JP4724421B2 (de) |
| KR (1) | KR20050050124A (de) |
| CN (1) | CN100431536C (de) |
| AT (1) | ATE429216T1 (de) |
| AU (2) | AU2003282758A1 (de) |
| BR (1) | BR0314540A (de) |
| CA (1) | CA2501347A1 (de) |
| DE (1) | DE60327335D1 (de) |
| ES (1) | ES2322954T3 (de) |
| IL (1) | IL167849A (de) |
| MX (1) | MXPA05003664A (de) |
| NO (1) | NO20051663L (de) |
| NZ (1) | NZ539328A (de) |
| PL (1) | PL216373B1 (de) |
| RU (1) | RU2330649C2 (de) |
| WO (1) | WO2004032913A1 (de) |
| ZA (1) | ZA200502744B (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2007206A4 (de) * | 2006-03-16 | 2010-12-08 | Yeda Res & Dev | Verfahren und zusammensetzung für den schutz von nervengewebe gegen schädigung durch hohe glutaminkonzentrationen |
| WO2009052075A2 (en) * | 2007-10-18 | 2009-04-23 | Allergan, Inc. | Method of treating motor disorders with alpha-2b adrenergic receptor agonists |
| WO2009052073A2 (en) * | 2007-10-18 | 2009-04-23 | Allergan, Inc. | Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists |
| US20100216857A1 (en) * | 2007-10-18 | 2010-08-26 | Luhrs Lauren M B | Method of treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione |
| CA2746295A1 (en) * | 2008-12-08 | 2010-07-08 | Allergan, Inc. | N-(1-phenyl-2-arylethyl)-4,5-dihydro-3h-pyrrol-2-amine compounds as subtype selective modulators of alpha2b or alpha2b and alpha2c adrenoceptors |
| SG10202107367SA (en) | 2016-12-31 | 2021-08-30 | Bioxcel Therapeutics Inc | Use of sublingual dexmedetomidine for the treatment of agitation |
| ES3004544T3 (en) | 2018-06-27 | 2025-03-12 | Bioxcel Therapeutics Inc | Film formulations containing dexmedetomidine and methods of producing them |
| US20240024288A1 (en) | 2019-07-19 | 2024-01-25 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
| US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4029792A (en) * | 1972-02-29 | 1977-06-14 | Pfizer Inc. | (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents |
| BE795970A (fr) * | 1972-02-29 | 1973-08-27 | Pfizer | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
| US5210076A (en) * | 1988-09-13 | 1993-05-11 | Berliner David L | Methods of treating Parkinson's disease using melanin |
| US6194415B1 (en) * | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
| BR9813381A (pt) * | 1997-12-04 | 2000-10-03 | Allergan Sales Inc | "derivados de imidazol substituìdo possuindo atividade semelhante a agonista em receptores adrenérgicos alfa 2b ou 2b/2c" |
| US6841684B2 (en) * | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| US6329369B1 (en) * | 1997-12-04 | 2001-12-11 | Allergan Sales, Inc. | Methods of treating pain and other conditions |
| US6313172B1 (en) * | 2000-04-13 | 2001-11-06 | Allergan Sales, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
| JP4927298B2 (ja) * | 2000-07-14 | 2012-05-09 | アラーガン、インコーポレイテッド | α−２−アドレナリンアゴニスト成分を含有する組成物 |
| AU2002248284A1 (en) * | 2000-11-01 | 2002-08-06 | Allergan, Inc. | Compositions for treatment of ocular neovascularization |
| US7091232B2 (en) * | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
-
2003
- 2003-10-07 JP JP2004543495A patent/JP4724421B2/ja not_active Expired - Fee Related
- 2003-10-07 DE DE60327335T patent/DE60327335D1/de not_active Expired - Lifetime
- 2003-10-07 PL PL376346A patent/PL216373B1/pl unknown
- 2003-10-07 US US10/680,879 patent/US20040138312A1/en not_active Abandoned
- 2003-10-07 NZ NZ539328A patent/NZ539328A/en not_active IP Right Cessation
- 2003-10-07 MX MXPA05003664A patent/MXPA05003664A/es active IP Right Grant
- 2003-10-07 CN CNB200380101115XA patent/CN100431536C/zh not_active Expired - Fee Related
- 2003-10-07 ES ES03774642T patent/ES2322954T3/es not_active Expired - Lifetime
- 2003-10-07 AU AU2003282758A patent/AU2003282758A1/en not_active Abandoned
- 2003-10-07 RU RU2005114504/14A patent/RU2330649C2/ru not_active IP Right Cessation
- 2003-10-07 AT AT03774642T patent/ATE429216T1/de not_active IP Right Cessation
- 2003-10-07 WO PCT/US2003/031809 patent/WO2004032913A1/en not_active Ceased
- 2003-10-07 KR KR1020057006114A patent/KR20050050124A/ko not_active Abandoned
- 2003-10-07 BR BR0314540-9A patent/BR0314540A/pt not_active Application Discontinuation
- 2003-10-07 EP EP03774642A patent/EP1549305B1/de not_active Expired - Lifetime
- 2003-10-07 CA CA002501347A patent/CA2501347A1/en not_active Abandoned
-
2005
- 2005-04-04 IL IL167849A patent/IL167849A/en active IP Right Grant
- 2005-04-04 NO NO20051663A patent/NO20051663L/no unknown
- 2005-04-05 ZA ZA200502744A patent/ZA200502744B/en unknown
-
2009
- 2009-11-20 AU AU2009238370A patent/AU2009238370B2/en not_active Ceased
-
2010
- 2010-12-03 JP JP2010270724A patent/JP2011057700A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN1703213A (zh) | 2005-11-30 |
| DE60327335D1 (de) | 2009-06-04 |
| RU2005114504A (ru) | 2005-10-27 |
| HK1081880A1 (zh) | 2006-05-26 |
| AU2009238370A1 (en) | 2009-12-17 |
| BR0314540A (pt) | 2005-07-26 |
| JP2011057700A (ja) | 2011-03-24 |
| WO2004032913A1 (en) | 2004-04-22 |
| AU2009238370B2 (en) | 2011-07-21 |
| JP2006504739A (ja) | 2006-02-09 |
| EP1549305A1 (de) | 2005-07-06 |
| AU2003282758A1 (en) | 2004-05-04 |
| MXPA05003664A (es) | 2005-06-08 |
| US20040138312A1 (en) | 2004-07-15 |
| PL216373B1 (pl) | 2014-03-31 |
| IL167849A (en) | 2011-04-28 |
| PL376346A1 (en) | 2005-12-27 |
| NZ539328A (en) | 2007-01-26 |
| ZA200502744B (en) | 2006-02-22 |
| JP4724421B2 (ja) | 2011-07-13 |
| ES2322954T3 (es) | 2009-07-02 |
| NO20051663L (no) | 2005-05-31 |
| RU2330649C2 (ru) | 2008-08-10 |
| CA2501347A1 (en) | 2004-04-22 |
| EP1549305B1 (de) | 2009-04-22 |
| CN100431536C (zh) | 2008-11-12 |
| KR20050050124A (ko) | 2005-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0309665A (pt) | Tratamento de deficiência de alfa-galactosidase a | |
| NO20050807L (no) | Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser | |
| ATE439140T1 (de) | Amylin und amylinagonisten für die behandlung von psychiatrischen erkrankungen und störungen | |
| WO2004026246A3 (en) | Methods of treating age associated memory impairment (aami), mild cognitive impairment (mci), and dementias with cell cycle inhibitors | |
| GB0223038D0 (en) | Therapeutic compounds | |
| BR0207526A (pt) | Composto, composição farmacêutica, e, métodos para o tratamento da dor, da enxaqueca, depressão, ansiedade, esquizofrenia, doença de parkinson ou derrame cerebral | |
| CY1115617T1 (el) | Χρηση της εποθιλονης κατα τη θεραπευτικη αγωγη νοσηματων τα οποια σχετιζονται με την πρωτεϊνη ταu εις τα οποια συμπεριλαμβανεται η νοσος του αlzheimer | |
| ATE409176T1 (de) | 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen | |
| ATE357438T1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
| ATE369861T1 (de) | Pteridin-derivate zur behandlung von erkrankungen im zusammenhang mit tnf-alpha | |
| DE60228073D1 (de) | Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen | |
| DE60304695D1 (de) | 7-ARYLSULFONAMID-2,3,4,5-TETRAHYDRO-1H-BENZOiDöAZEPINE MIT 5-HT6 REZEPTOR AFFINITÄT ZUR BEHANDLUNG VON ZENTRALNERVENSYSTEMERKRANKUNGEN | |
| DE60008753D1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
| ATE423990T1 (de) | Verfahren und zusammensetzungen zur behandlung von uveitis | |
| TR200101149T2 (tr) | Dış retina bozukluklarının tedavisi. | |
| CY1106409T1 (el) | Παραγωγα κινολινης | |
| NO20044530L (no) | Fremgangsmate for behandling av kognitive forstyrrelser | |
| DE60327335D1 (de) | Alpha 2b oder 2b/2c adrenozeptor-agonisten zur behandlung von morbus alzheimer und morbus parkinson | |
| ATE355054T1 (de) | Verfahren und verbindungen zur behandlung der depression | |
| CY1109666T1 (el) | Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας | |
| ATE425967T1 (de) | Piperazin und piperadin-derivate fur die behandlung von neurologischen krankheiten | |
| BR0314541A (pt) | Tratamento de demência e doença de parkinson | |
| MXPA05004121A (es) | Metodos para tratar la enfermedad de ojo reseco con lantibioticos. | |
| NO20054034L (no) | Fremgangsmate for behandling av hypotyroidisme. | |
| ATE482217T1 (de) | Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |